# Head-to-head bispecific vs CAR-T in second-line LBCL

Source: https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/  
OnCo record `idea-bispecific-vs-car-t-second-line` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nobody has directly compared an off-the-shelf bispecific with CAR-T in the same patients; a trial would settle where each belongs.

## Summary

The idea is a head-to-head randomised trial of an off-the-shelf CD20 bispecific, epcoritamab or glofitamab with chemotherapy, against the CAR-T product axicabtagene ciloleucel in second-line large B-cell lymphoma. CAR-T has phase 3 event-free and overall survival wins in early relapse, while bispecifics have single-arm data and one mixed phase 3 in EPCORE DLBCL-1, but can be repeated, arrive within a week, and win on access and cost. The hypothesis is that a bispecific with chemotherapy is non-inferior to axi-cel on event-free survival at lower cost with comparable cytokine release syndrome. The test is a randomised non-inferiority trial with quality of life and cost as secondary endpoints; the speculative idea addresses the manufacturing bottleneck.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: Epcoritamab or glofitamab with chemotherapy is non-inferior to axi-cel on EFS in second-line LBCL with a lower cost and comparable CRS.
- Rationale: Both redirect T cells to CD19/CD20+ cells; bispecifics can be repeated and are available in a week.
- Proposed test: Randomised non-inferiority trial with EFS primary, quality-of-life and cost secondary; ctDNA-defined stratification.
- Maturity: speculative

## Sources

- ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early (New England Journal of Medicine 2022): https://doi.org/10.1056/NEJMoa2116133
- ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma (New England Journal of Medicine 2017): https://doi.org/10.1056/NEJMoa1707447

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Glofitamab](https://onco.cc/drugs/glofitamab/)
- key papers: [Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/), [Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial](https://onco.cc/key-papers/paper-glofitamab-dlbcl-lancet-2024/), [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/idea-bispecific-vs-car-t-second-line.json